

Michael S Saag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6638056/publications.pdf>

Version: 2024-02-01

133
papers

17,463
citations

50276

46
h-index

16650

123
g-index

137
all docs

137
docs citations

137
times ranked

13849
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort. <i>Clinical Infectious Diseases</i> , 2022, 75, 715-718.	5.8	2
2	HIV Symptom Clusters Are Similar Using the Dimensions of Symptom Occurrence and Distress. <i>Journal of Pain and Symptom Management</i> , 2022, , .	1.2	0
3	Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science. <i>Physiological Reviews</i> , 2022, 102, 1569-1577.	28.8	9
4	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 1900-1909.	5.8	22
5	A mentor training workshop focused on fostering diversity engenders lasting impact on mentoring techniques: Results of a long-term evaluation. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e116.	0.6	8
6	HIV Viremia and Risk of Stroke Among People Living with HIV Who Are Using Antiretroviral Therapy. <i>Epidemiology</i> , 2021, 32, 457-464.	2.7	10
7	A 12-year retrospective evaluation of anal pre-cancerous lesions and cancer in people living with HIV-1 infection in the Southeastern U.S. <i>Infectious Agents and Cancer</i> , 2021, 16, 14.	2.6	8
8	Antiretroviral Drug Recommendations for HIV Treatment and Preventionâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 889.	7.4	0
9	Indoleamine 2,3 Dioxygenase, Age, and Immune Activation in People Living with Hiv. <i>Journal of Investigative Medicine</i> , 2021, 69, 1238-1244.	1.6	6
10	Decreased Alcohol Consumption in an Implementation Study of Computerized Brief Intervention among HIV Patients in Clinical Care. <i>AIDS and Behavior</i> , 2021, 25, 4074-4084.	2.7	12
11	HIV Infection â€” Screening, Diagnosis, and Treatment. <i>New England Journal of Medicine</i> , 2021, 384, 2131-2143.	27.0	29
12	Changes in lipidomic profile by anti-retroviral treatment regimen. <i>Medicine (United States)</i> , 2021, 100, e26588.	1.0	1
13	Mortality Among Persons Entering HIV Care Compared With the General U.S. Population. <i>Annals of Internal Medicine</i> , 2021, 174, 1197-1206.	3.9	31
14	Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 86-95.	2.1	15
15	Drug and alcohol use among people living with HIV in care in the United States by geographic region. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1569-1576.	1.2	15
16	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
17	The impact of COVID-19 on mentoring early-career investigators. <i>Medicine (United States)</i> , 2021, 100, e27423.	1.0	5
18	Developing COVID-19 vaccine policy in increments. <i>Lancet, The</i> , 2021, 398, 1382-1383.	13.7	0

#	ARTICLE	IF	CITATIONS
19	Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. <i>Clinical Infectious Diseases</i> , 2020, 70, 867-874.	5.8	19
20	Whatâ€™s All This Fuss I Hear About Viral â€œBlipsâ€?. <i>Clinical Infectious Diseases</i> , 2020, 70, 2710-2711.	5.8	5
21	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1651.	7.4	329
22	Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies. <i>IScience</i> , 2020, 23, 101711.	4.1	4
23	Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. <i>Aids</i> , 2020, 34, 2051-2059.	2.2	16
24	Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death. <i>Epidemiology</i> , 2020, 31, 704-712.	2.7	8
25	Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness. <i>Journal of Infectious Diseases</i> , 2020, 222, S365-S375.	4.0	7
26	Genetic architecture of cardiometabolic risks in people living with HIV. <i>BMC Medicine</i> , 2020, 18, 288.	5.5	11
27	Misguided Use of Hydroxychloroquine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2161.	7.4	72
28	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. <i>PLoS ONE</i> , 2020, 15, e0227041.	2.5	15
29	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. , 2020, 15, e0227041.		0
30	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. , 2020, 15, e0227041.		0
31	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. , 2020, 15, e0227041.		0
32	Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. , 2020, 15, e0227041.		0
33	Physical Functioning Among Patients Aging With Human Immunodeficiency Virus (HIV) Versus HIV Uninfected: Feasibility of Using the Short Physical Performance Battery in Clinical Care of People Living With HIV Aged 50 or Older. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz038.	0.9	16
34	Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virusâ€“Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz100.	0.9	15
35	Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e141-e147.	2.1	9
36	Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 572-577.	2.1	12

#	ARTICLE	IF	CITATIONS
37	Marijuana Use Is Not Associated With Changes in Opioid Prescriptions or Pain Severity Among People Living With HIV and Chronic Pain. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 231-237.	2.1	15
38	Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, e6-e9.	2.1	1
39	Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men who have Sex with Men and Men who have Sex with Women Engaged in Routine HIV Care in the United States. <i>AIDS and Behavior</i> , 2019, 23, 1634-1646.	2.7	16
40	Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort. <i>AIDS and Behavior</i> , 2019, 23, 627-635.	2.7	21
41	Intervention Mapping to develop a Social Cognitive Theory-based intervention for chronic pain tailored to individuals with HIV. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 9-16.	1.1	12
42	Increased non-AIDS mortality among persons with AIDS defining events after antiretroviral therapy initiation. <i>Journal of the International AIDS Society</i> , 2018, 21, e25031.	3.0	38
43	Point-of-Care Urine Ethyl Glucuronide Testing to Detect Alcohol Use Among HIV-Hepatitis B Virus Coinfected Adults in Zambia. <i>AIDS and Behavior</i> , 2018, 22, 2334-2339.	2.7	21
44	Predictors of Longitudinal Trajectories of Alcohol Consumption in People with HIV. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 561-570.	2.4	23
45	Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2154.	7.4	0
46	Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 77-82.	2.1	47
47	Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 916-921.	1.1	2
48	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. <i>Aids</i> , 2018, 32, 1361-1367.	2.2	14
49	HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015. <i>Annals of Internal Medicine</i> , 2018, 169, 376.	3.9	91
50	Chronic hepatitis B virus monoinfection at a university hospital in Zambia. <i>World Journal of Hepatology</i> , 2018, 10, 622-628.	2.0	4
51	Using Patient Perspectives to Inform the Development of a Behavioral Intervention for Chronic Pain in Patients with HIV: A Qualitative Study. <i>Pain Medicine</i> , 2017, 18, pnw150.	1.9	13
52	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	4.7	10
53	Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States. <i>Clinical Infectious Diseases</i> , 2017, 64, 1591-1596.	5.8	14
54	Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 568-576.	2.1	110

#	ARTICLE	IF	CITATIONS
55	Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment. <i>AIDS and Behavior</i> , 2017, 21, 1914-1925.	2.7	102
56	Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States. <i>JAMA Cardiology</i> , 2017, 2, 260.	6.1	61
57	Brief Report: Factors Associated With the Selection of Initial Antiretroviral Therapy From 2009 to 2012. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 60-64.	2.1	7
58	Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders [*] . <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 177-184.	1.2	12
59	Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 534-545.	1.1	6
60	The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals. <i>AIDS and Behavior</i> , 2017, 21, 1878-1884.	2.7	12
61	Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. <i>Retrovirology</i> , 2017, 14, 35.	2.0	12
62	Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities. <i>Journal of Infectious Diseases</i> , 2017, 216, S581-S587.	4.0	12
63	Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. <i>Clinical Infectious Diseases</i> , 2017, 64, 1343-1349.	5.8	43
64	Implementation of Computer-delivered Brief Alcohol Intervention in HIV Clinical Settings: Who Agrees to Participate?. <i>Journal of Addiction Research & Therapy</i> , 2016, 07, .	0.2	8
65	Unanticipated Effects of New Drug Availability on Antiretroviral Durability: Implications for Comparative Effectiveness Research. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw109.	0.9	10
66	Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 437-443.	2.1	43
67	Factors Associated with Prescription of Opioids and Co-prescription of Sedating Medications in Individuals with HIV. <i>AIDS and Behavior</i> , 2016, 20, 687-698.	2.7	26
68	Suitability of the PROMIS alcohol use short form for screening in a HIV clinical care setting. <i>Drug and Alcohol Dependence</i> , 2016, 164, 113-119.	3.2	13
69	HIV primary care providers' Screening, knowledge, attitudes and behaviors related to alcohol interventions. <i>Drug and Alcohol Dependence</i> , 2016, 161, 59-66.	3.2	39
70	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	1.9	43
71	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160460.	2.5	86
72	Diminished CD103 (aEb7) Expression on Resident T cells from the Female Genital Tract of HIV-positive women. <i>Pathogens and Immunity</i> , 2016, 1, 371.	3.1	23

#	ARTICLE	IF	CITATIONS
73	A Randomized Controlled Trial Protocol to Evaluate the Effectiveness of an Integrated Care Management Approach to Improve Adherence Among HIV-Infected Patients in Routine Clinical Care: Rationale and Design. JMIR Research Protocols, 2016, 5, e156.	1.0	2
74	The Silent Epidemic - Frailty and Aging with HIV. , 2016, 1, 6-17.		8
75	Quantitative Evaluation of an Instrument to Identify Chronic Pain in HIV-Infected Individuals. AIDS Research and Human Retroviruses, 2015, 31, 623-627.	1.1	17
76	Dynamic Visual Display of Treatment Response in HIV-Infected Adults. Clinical Infectious Diseases, 2015, 61, e1-e4.	5.8	6
77	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet, The, 2015, 385, 2606-2615.	13.7	521
78	Editorial Commentary: Fixing a Hole in the HIV Safety Net. Clinical Infectious Diseases, 2015, 60, 126-127.	5.8	8
79	“Two Pains Together”™: Patient Perspectives on Psychological Aspects of Chronic Pain while Living with HIV. PLoS ONE, 2014, 9, e111765.	2.5	22
80	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Medicine, 2014, 11, e1001718.	8.4	100
81	HIV/AIDS. Infectious Disease Clinics of North America, 2014, 28, ix-x.	5.1	1
82	Enhanced Personal Contact With HIV Patients Improves Retention in Primary Care: A Randomized Trial in 6 US HIV Clinics. Clinical Infectious Diseases, 2014, 59, 725-734.	5.8	131
83	Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet, The, 2014, 383, 2222-2231.	13.7	430
84	HIV/AIDS. Infectious Disease Clinics of North America, 2014, 28, xv-xvi.	5.1	1
85	Engagement in Human Immunodeficiency Virus Care. Infectious Disease Clinics of North America, 2014, 28, 355-369.	5.1	33
86	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. Clinical Infectious Diseases, 2014, 59, 287-297.	5.8	136
87	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009. Clinical Infectious Diseases, 2013, 56, 1174-1182.	5.8	90
88	Pain is Independently Associated with Impaired Physical Function in HIV-Infected Patients. Pain Medicine, 2013, 14, 1985-1993.	1.9	75
89	Effect of Persistency of First-Line HIV Antiretroviral Therapy on Clinical Outcomes. AIDS Research and Human Retroviruses, 2013, 29, 698-703.	1.1	4
90	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. Aids, 2013, 27, 803-813.	2.2	70

#	ARTICLE	IF	CITATIONS
91	Prioritizing CD4 Count Monitoring in Response to ART in Resource-Constrained Settings: A Retrospective Application of Prediction-Based Classification. <i>PLoS Medicine</i> , 2012, 9, e1001207.	8.4	8
92	Pain, Mood, and Substance Abuse in HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 164-170.	2.1	113
93	Migrating from a legacy fixed-format measure to CAT administration: calibrating the PHQ-9 to the PROMIS depression measures. <i>Quality of Life Research</i> , 2011, 20, 1349-1357.	3.1	51
94	The ghosts of Christmas past. How would those we've lost guide us today?. <i>Positively Aware: the Monthly Journal of the Test Positive Aware Network</i> , 2011, 23, 10-2.	0.0	0
95	Durability of Initial Antiretroviral Therapy in a Resource-Constrained Setting and the Potential Need for Zidovudine Weight-Based Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 215-221.	2.1	49
96	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , 2010, 7, 45.	1.7	73
97	How Do HIV Elite Controllers Do What They Do?. <i>Clinical Infectious Diseases</i> , 2010, 51, 239-241.	5.8	43
98	Comparative Efficacy versus Effectiveness of Initial Antiretroviral Therapy in Clinical Trials versus Routine Care. <i>Clinical Infectious Diseases</i> , 2010, 50, 574-584.	5.8	17
99	Maraviroc versus Efavirenz, Both in Combination with Zidovudine and Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2010, 201, 803-813.	4.0	241
100	Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 Weeks. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1279-1285.	1.1	23
101	A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1. <i>Journal of Infectious Diseases</i> , 2009, 199, 1638-1647.	4.0	127
102	HIV/AIDS: The Only Thing Constant?. <i>Journal of the National Medical Association</i> , 2009, 101, 1299-1300.	0.8	0
103	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009, 206, 1273-1289.	8.5	684
104	Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 1442-1455.	27.0	320
105	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7552-7557.	7.1	1,708
106	Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. <i>International Journal of Epidemiology</i> , 2008, 37, 948-955.	1.9	242
107	Short-Term Discontinuation of HAART Regimens More Common in Vulnerable Patient Populations. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1347-1355.	1.1	44
108	Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. <i>Aids</i> , 2008, 22, 1951-1960.	2.2	109

#	ARTICLE	IF	CITATIONS
109	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. <i>Antiviral Therapy</i> , 2008, 13, 959-967.	1.0	65
110	Can Routine Clinical Markers Be Used Longitudinally to Monitor Antiretroviral Therapy Success in Resourceâ€limited Settings?. <i>Clinical Infectious Diseases</i> , 2007, 44, 135-138.	5.8	43
111	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , 2007, 36, 294-301.	1.9	176
112	Failure to Establish HIV Care: Characterizing the "No Show" Phenomenon. <i>Clinical Infectious Diseases</i> , 2007, 45, 127-130.	5.8	106
113	Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in Zambia. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 782.	7.4	603
114	Emtricitabine, a New Antiretroviral Agent with Activity against HIV and Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2006, 42, 126-131.	5.8	71
115	Distribution of Health Care Expenditures for HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2006, 42, 1003-1010.	5.8	148
116	Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. <i>Nature Medicine</i> , 2005, 11, 1170-1172.	30.7	467
117	Once-Weekly Epoetin Alfa Improves Quality of Life and Increases Hemoglobin in Anemic HIV+Patients. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1037-1045.	1.1	26
118	Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 180.	7.4	125
119	Treatment for Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 251.	7.4	482
120	Antibody neutralization and escape by HIV-1. <i>Nature</i> , 2003, 422, 307-312.	27.8	2,233
121	Duration of Highly Active Antiretroviral Therapy Regimens. <i>Clinical Infectious Diseases</i> , 2003, 37, 714-722.	5.8	88
122	The impact of highly active antiretroviral therapy on HIV-specific immune function. <i>Aids</i> , 2001, 15, S4-S10.	2.2	12
123	Prolonged Suppression of Human Immunodeficiency Virus Type 1 RNA during Dual Nucleoside Reverseâ€transcriptaseâ€inhibitor Therapy in Clinical Practice. <i>Clinical Infectious Diseases</i> , 2000, 31, 1095-1097.	5.8	3
124	HIV-1 and HAART: A time to cure, a time to kill. <i>Nature Medicine</i> , 1999, 5, 609-611.	30.7	50
125	Treatment of Fluconazole-Refractory Oropharyngeal Candidiasis with Itraconazole Oral Solution in HIV-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1413-1417.	1.1	56
126	Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA. <i>Journal of Experimental Medicine</i> , 1999, 189, 1545-1554.	8.5	195

#	ARTICLE	IF	CITATIONS
127	Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. <i>Journal of Clinical Investigation</i> , 1999, 103, 1391-1398.	8.2	293
128	Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. <i>Nature Medicine</i> , 1998, 4, 1302-1307.	30.7	985
129	Pharmacokinetics of an anti-HIV human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 44-53.	4.7	122
130	Viral dynamics in human immunodeficiency virus type 1 infection. <i>Nature</i> , 1995, 373, 117-122.	27.8	3,369
131	<i>Response</i> : Effect of Platelet-Associated Virus on Assays of HIV-1 in Plasma. <i>Science</i> , 1993, 262, 1585-1586.	12.6	1
132	<i>Response</i> : Effect of Platelet-Associated Virus on Assays of HIV-1 in Plasma. <i>Science</i> , 1993, 262, 1585-1586.	12.6	1
133	Extensive variation of human immunodeficiency virus type-1 in vivo. <i>Nature</i> , 1988, 334, 440-444.	27.8	450